ClinicalTrials.gg
CompletedNCT03409198ICONUpdated Oct 15, 2024

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer

A Phase 2 interventional study of Ipilimumab and Nivolumab in Breast Cancer, Hormone Receptor Positive Tumor and Metastatic Breast Cancer, sponsored by Oslo University Hospital. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Oslo University Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies testing ipilimumab in Breast Neoplasms — 3 open to participants now, 7 under way, 1 of them phase 3. Ipilimumab · Breast Neoplasms.

Enrollment
4th of 15
82 · median 30
Started
2018
with 2 others
Phase 2
9 of 15
1 open now
Registered
7th of 15
by date
Lead sponsor
1 of 15
Oslo University Hospital

Among the 15 studies testing ipilimumab in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 2, and was the 7th registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 15 studies testing ipilimumab in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ipilimumab in Breast Neoplasms, or all of them as a file.
02

Study summary

Breast cancer is rarely curable after metastasis, and the therapeutic options are limited. Interestingly, the host immune response is strongly predictive for the effect of chemotherapy in subgroups of patients with breast cancer. The aim is to release the brake on the immune response by use of ipilimumab, which blocks CTLA-4 and may deplete regulatory T cells, combined with nivolumab (anti PD1). Importantly, it is possible that non-responders to nivolumab/ipilimumab (nivo/ipi) can be turned responders by use of immunogenic chemotherapy.

Read the detailed description

There is compelling evidence from animal studies, supported by data from humans, that some chemotherapeutic agents are immunogenic. Doxorubicin and cyclophosphamide have been shown to be particularly powerful inducers of immunogenic cell death. Both agents fulfil 5/5 criteria established for assessing the immunogenicity of different chemotherapeutic drugs. There is also strong evidence from humans, particularly in breast cancer, indicating that the clinical effect of doxorubicin and cyclophosphamide depends on the host immune response. Further, these agents have been shown to induce a Type I interferon immune response in breast cancer. Taken together, there is a strong rationale for synergy between doxorubicin/cyclophosphamide and PD-1/CTLA-4 blockade. The trial combines nivolumab and ipilimumab with established 1st choice chemotherapy in patients with metastatic hormone reseptor positive breast cancer. Nivolumab/ipilimumab (nivo/ipi) may i) potentiate the patient´s spontaneous anti-tumor immune response ii) synergize with chemotherapeutic agents that induce immunological cell death

03

Conditions studied

  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • Metastatic Breast Cancer

Keywords

  • Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. hormone receptor positive breast cancer (primary or recurrent), defined as ER+ >1% in metastatic (archival material or study biopsy) or cytology and negative in the last biopsy or cytology evaluable for HER2. HER2-analysis is to be perfomed according to national criteria.
  2. Adequate core or excisional study biopsy of a tumor lesion. Lesions in previously irradiated areas may only be used for the biopsy if the lesion has appared or progressed after radiation. No anti-tumor treatment is allowed between the time point for biopsy and study entry.
  3. Measurable metastatic disease according to
  4. (ECOG) performance status of 0 or 1
  5. Signed Form
  6. Women or men aged ≥ 18 years
  7. A minimum of 12 months from /neoadjuvant chemotherapy with antracyclins to relapse disease
  8. A maximum of one previous line with chemotherapy in the metastatic setting
  9. Chemotherapy is considered as preferred treatment
  10. Previous endocrine and targeted therapy is allowed
  11. No use of systemic at study entry
  12. Female subject of should have a negative urine or serum pregnancy within 7 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  13. Female subjects of childbearing potential should agree to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \< 1% per year, during the treatment period and for at least 5 months after the last dose of study therapy.
  14. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy
  15. Able to swallow and retain orally administered medication
  16. Adequate organ function as defined in Table 1

Exclusion criteria

Exclusion Criteria:

  1. other than breast cancer within 5 years prior to randomization, with the exception of those with a negligible risk of or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
  2. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 8 weeks prior to randomization
  3. Known CNS disease, except for asymptomatic , provided all of the following criteria are met:

    1. outside the CNS
    2. Asymptomatic for CNS disease > 4 weeks
    3. No ongoing requirement for as therapy for CNS disease
    4. No radiation of brain lesions within 2 weeks prior to randomization
    5. No
  4. Uncontrolled pleural effusion, pericardial effusion, or ascites. Patients with indwelling catheters (e.g., PleurX®) are allowed
  5. Uncontrolled tumor-related pain. Patients requiring narcotic pain medication must be on a stable regimen at study entry. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomization
  6. Ionized calcium > 1.2 x UNL. The use of bisphosphonates is allowed
  7. Pregnant or breastfeeding
  8. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)
  9. Significant cardiovascular disease, such as (NYHA) cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina Patients with a known (LVEF) \< 40% will be excluded. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF \< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
  10. Severe infection within 21 days prior to randomization, requiring hospitalization
  11. Received oral or IV antibiotics within 1 week prior to Cycle 1, Day 1. Patients receiving routine antibiotic prophylaxis (e.g., to prevent exacerbation or for dental extraction) are eligible
  12. Major surgical procedure within 21 days prior to randomization or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis. Placement of central venous access catheter(s) is not considered a major surgical procedure and is therefore permitted
  13. A history of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins
  14. Known hypersensitivity to any of the components of the products
  15. A history of disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or drugs). Replacement therapy (e.g., thyroxin, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., no psoriatic arthritis) are permitted provided that they meet all of the following conditions:

    1. Rash must cover less than 10% of body surface area.
    2. Disease is well controlled at baseline and only requiring low potency topical steroids
    3. No acute exacerbations of underlying condition within the last 12 months (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids)
  16. Undergone allogeneic stem cell or solid organ transplantation
  17. A history of idiopathic pulmonary fibrosis pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  18. A positive test for
  19. Active (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or . Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
  20. Active tuberculosis
  21. Currently receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
  22. Received treatment with immune checkpoint modulators, including , anti-PD-1, or anti-PD-L1 therapeutic antibodies
  23. Received treatment with systemic immunostimulatory agents (including but not limited to interferons or IL-2) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization
  24. Received treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial

    1. Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study
    2. Patients with a history of allergic reaction to IV contrast requiring steroid pre-treatment should have baseline and subsequent tumor assessments performed using MRI
    3. The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed
  25. Received anti-cancer therapy (medical agents or radiation) within 2 weeks prior to study Cycle 1, Day 1. Palliative radiotherapy for bone lesions is allowed up to 7 days before start of therapy.
  26. A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator
  27. Known psychiatric or substance abuse disorders that would interfere with cooperation and the requirements of the trial
  28. Received a within 30 days of planned start of study therapy, or is expected to receive such a vaccine while on therapy

    a. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

  29. Any reason why, in the opinion of the investigator, the patient should not participate
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Active comparator
    Arm A

    Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)

    Drug: Pegylated liposomal doxorubicin · Drug: Cyclophosphamide

  • Experimental
    Arm B

    Chemo + ipilimumab + nivolumab

    Drug: Ipilimumab · Drug: Nivolumab · Drug: Pegylated liposomal doxorubicin · Drug: Cyclophosphamide

Interventions

  • Ipilimumab blocks CTLA-4 and may deplete regulatory T cells

    Also known as: Yervoy

  • Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.

    Also known as: Opdivo

  • Chemotherapy

  • Chemotherapy

06

What researchers measure

Primary outcomes

  1. Toxicity: CTCAE v4.0

    Assessment of toxicity of combined treatment with ipilimumab, nivolumab, pegylated liposomal doxorubicin and cyclophosphamide (ipi/nivo/chemo)

    Time frame: 3 years

  2. Progression-free survival (PFS)

    Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: Progression-free survival (PFS); compare the PFS rates when 95% of patients in the control croup have PD

    Time frame: We expect to reach the data-driven time point for PFS-analysis (95% PFS in the control group) approximately 3 years after the study opens. If this is not met within 24 months after inclusion of the last patient, the PFS-analysis will be performed at this

Secondary outcomes

  1. Duration of Response (DR)

    Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: duration of response (DR)

    Time frame: 3 years

  2. Overall Survival (OS)

    Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: overall survival (OS)

    Time frame: 5 years

  3. Duration of Response (DR) in cross-over arm

    Assessment of clinical response in ipi/nivo group: duration of response (DR)

    Time frame: 3 years

  4. Overall Suvival (OS) in cross-over arm

    Assessment of clinical response in ipi/nivo group: overall survival (OS)

    Time frame: 5 years

  5. Toxicity, cross-over arm, CTCAE v4.0

    Assessment of toxicity of ipi/nivo (without chemotherapy) in cross-over arm

    Time frame: 3 years

  6. Objective tumor Response Rate (ORR)

    Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: Objective tumor response rate (ORR)

    Time frame: 3 years

  7. Durable tumor Response Rate (DRR)

    Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: durable tumor response rate (DRR; \>6 months)

    Time frame: 3 years

  8. Objective tumor Response Rate (ORR) in cross-over arm

    Assessment of clinical response in ipi/nivo group: Objective tumor response rate (ORR)

    Time frame: 3 years

  9. Durable tumor Response Rate (DRR) in cross-over arm

    Assessment of clinical response in ipi/nivo group: durable tumor response rate (DRR; \>6 months)

    Time frame: 3 years

  10. Clinical Benefit Rate (CBR)

    Proportion of patients with an objective tumor response or with stable disease lasting at least 6 months

    Time frame: 3 years

  11. Clinical Benefit Rate (CBR) in cross-over arm

    Proportion of patients with an objective tumor response or with stable disease lasting at least 6 months

    Time frame: 3 years

  12. PD-L1 expression

    Assessment of PD-L1 expression, mutation load and immune gene expression as biomarkers for clinical response

    Time frame: 3 years

  13. Chalder Fatigue Questionnaire (FQ)

    Assessment of patient reported outcomes, as measured by the Chalder Fatigue Questionnaire (FQ)

    Time frame: 3 years

  14. Pain intensity

    Assessment of patient reported outcomes, as measured by an 11 point Numerical Rating Scale (NRS) for pain intensity

    Time frame: 3 years

  15. EORTC QLQ-C15-PAL

    Assessment of patient reported outcomes, as measured by the EORTC QLQ-C15-PAL

    Time frame: 3 years

  16. Biological response in molecular subtypes of breast cancer

    Comparison of clinical and biological response in molecular subtypes of breast cancer

    Time frame: 3 years

Other outcomes

  1. Immunological response

    Assessment of immunological response. In selected patients, the specificity of T-cell responses will be analysed. The analysis will be based neoantigen prediction and will be performed by multimer technology.

    Time frame: 3 years

  2. Biomarkers for clinical response

    Identification of biomarkers for clinical response by use of gene profiling, pathology, cytokine assays and other analysis on material from study patients. The following predefined biomarkers will be compared between responders and non-responders: PD-L1 in biopsies, immune gene signature in biopsies. Further explorative investigations will be performed to identify new candidate biomarker signatures.

    Time frame: 3 years

  3. Biomarkers for toxicity

    Identification of biomarkers for toxicity by use of gene profiling, pathology, cytokine assays and other analysis on material from study patients. The analysis is explorative and will be performed to identify new candidate biomarker signatures. The candidate signatures will be compared between patients with and without immune related adverse events.

    Time frame: 3 years

  4. Assessment of changes in the immunological milieu in tumor and peripheral blood

    Considering each study arm separately, and by comparing arm A to arm B. The assessment will be performed by flow cytometry and CyTOF of immune cells, and by gene expression profiling of tumor biopsies. In periferal blood,the frequency of immune cell subsets will be determined and compared between baseline and later timepoints. In biopsies, gene expression profiles will be compared between baseline and later timepoints.

    Time frame: 3 years

07

Study locations

6 sites
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Cliniques universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • CHU UCL Namur
    Namur, 5000, Belgium
  • Soerlandet Hospital HF Kristiansand
    Kristiansand, Norway
  • Oslo University Hospital
    Oslo, Norway
  • Stavanger University Hospital
    Stavanger, 4011, Norway
08

References and documents

Publications

  • Andresen NK, Rossevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred O, Russnes HG, Lereim RR, Chauhan SK, Lingjaerde OC, Dunn C, Naume B, Kyte JA. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. J Immunother Cancer. 2024 Jan 19;12(1):e007990. doi: 10.1136/jitc-2023-007990. PubMed 38242720 ↗
  • Kyte JA, Andresen NK, Russnes HG, Fretland SO, Falk RS, Lingjaerde OC, Naume B. ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. J Transl Med. 2020 Jul 3;18(1):269. doi: 10.1186/s12967-020-02421-w. PubMed 32620163 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in May 2022, 51 months.

Of 1,071 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 51 months is close to that.

Counting every sponsor, half of 1,303 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2017
First posted
Jan 24, 2018
StartActual
Jan 21, 2018
Primary completionActual
May 11, 2022
CompletionActual
May 11, 2022
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03409198
Collaborators
Bristol-Myers Squibb, Helse Stavanger HF, Helse Sor-Ost, Sorlandet Hospital HF, Jules Bordet Institute, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Centre Hospitalier Universitaire UCLouvain Namur
Responsible party
Jon Amund Kyte (Principal Investigator, Oslo University Hospital) — Principal investigator
First posted
Jan 24, 2018
Start date
Jan 21, 2018
Primary completion
May 11, 2022
Completion
May 11, 2022
Last update
Oct 15, 2024

Study contacts

Jon Amund Kyte
principal investigator · Oslo University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Nivolumab

Start the discussion